Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST trial of omalizumab in carotid atherosclerotic plaques
NL-OMON60118Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in carotid atheroma (CAS) and atherosclerosis comparing Omalizumab with Placebo (2 arms). Primary endpoint: Percentage of mast cell activation. Started Jun 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
carotid atheroma (CAS)atherosclerosis
Beyond the preview
Go deeper on NL-OMON60118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60118.